Andersons pediatric cardiology 2337
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (78.21 KB, 3 trang )
teratomas,973–974,973f
tuberoussclerosiscomplex,971
tumorsoftheatrioventricularnode,975
vasculartumors,974,974f
Cardiacvalves
anatomyof,26–28
areaof,calculation,usingDopplerechocardiography,308
arterialvalves,27
atrioventricularvalves,26–27,27f
embryologyof,46
ofarterialvalves,46
ofatrioventricularcanal,46
ofsinoatrialjunction,46
papillarymuscleof,26–27
positionsof,18f
septalstructuresof,27–28
Cardiacveins,terminationof,withisomericatrialappendages,444–447
Cardinalveins,morphogenesisof,458f
Cardiologists,asresourceofcommunityandadvocatesforpatients,1494
Cardiology,1482t
Cardiomyocyte
contractilityanddevelopment-specializedmachineryof,71–77
actinandtitin,72–73
excitationandcontraction,75–77,76f
mitochondriaandenergyproduction,74–75,75f
myosin,71–72
sarcomere,71,71f
troponin,73–74
developmentandmaintenanceof,67–71
nucleusandDNA,67
proteinsynthesisanddegradation,68–71,69f–70f
RNA,67–68,68f
inmyocardialdevelopment,62,63f
Cardiomyopathy,1145–1165,1522–1523
anthracycline-induced,exercisetestingfor,401
dilated,1426
drug-induced,1112
hypertrophic,77
hypertrophic,pacingfor,366
mitochondrial,1148
recommendedscreeningfor,1543
Cardio-oncology,1167–1172
Cardioplegia,incardiopulmonarybypass,230
Cardioprotection,forcancertherapy-relatedcardiotoxicity,1171–1172
Cardiopulmonarybypass(CPB),225–234
acid-basemanagementand,229
α-adrenergicblockadein,232
alteredcerebralflowofbloodandmetabolismin,232
anesthesiafor,229
anticoagulationin,230
cardioplegiain,230
cerebralinjuryrelatedto,pathwaysof,229–230
cerebralprotectionand,229
circuitryof,225–227,226f–227f
conductof,227–231
considerationsattheendof,232–234
cooling,strategiesfor,228–229
corticosteroidsin,231–232
deephypothermiccirculatoryarrestin,230–231
glucose,controlof,232
hematocritduring,1399
hemodilutionin,228
intraoperativeechocardiographyin,233
monitoringin,233
myocardialprotectionand,230
pharmacologicandmechanicaladjunctsin,231–232
postconditioningin,233
postoperativeextracorporealsupportin,233–234,234f
preconditioningin,232
duringpregnancy,1449
ratesofflowin,227–228
selectiveantegradecerebralperfusionin,231
strategyfor,1398–1399
temperatureregulationin,228
ultrafiltrationin,232
Cardiopulmonaryexercisestresstesting,ofanomalousaorticoriginofa
coronaryartery,874
Cardiopulmonaryexercisetesting(CPET),forcancertherapy-related
cardiotoxicity,1171
Cardiopulmonaryinteractions
inchildrenwithabnormalitiesofdiastolicfunction,1183
inchildrenwithsystolicventriculardysfunction,1182–1183
infunctionallyuniventricularcirculationafterstage1palliation,1183
inhealthycirculation,1182,1182f
Cardiopulmonaryresuscitation,inKawasakisyndrome,994
Cardiorenalsyndromes
acute,interventionsof,1422–1425
classificationof,1421–1427,1422t
acutecardiorenalsyndrome,1421,1422t
acutekidneydisease,associatedwithcardiacsurgery,1421–1422,1423t
heartfailure,1426–1427
interventionsof,1422–1425,1424t–1425t
post-cardiacsurgeryfor,1421,1423f,1423t
translationalresearchandfutureinterventions,1425–1426,1426f,1426t
Cardiotoxictreatmentexposures,inchildhoodandadolescentcancers,1168t
Cardiotropicsupport,forhemodynamicallysignificantarterialduct,198
Cardiovascularcare,forcongenitallymalformedhearts,208–209,209f
Cardiovasculardrugs,foracutecirculatoryfailure,1183–1185,1184t
complexcirculationsin,1185
maturationalinfluencesin,1183–1185
pulmonaryvasculaturein,1185
Cardiovascularmonitoring,forprematurity,211
Cardiovascularriskfactors,423–437,424f,424t
